-
5 days ago | 
rheumnow.com | Jack Cush
An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA. Denosumab plays an important role in OP guidelines, often secondary to antiresorptive agents such as bisphosphonates (usual first-line therapy). Yet, denosumab is recommended as it is more convenient, has fewer gastrointestinal adverse effects, and its use is increasing while bisphosphonate use remains constant. 3-year persistence with denosumab and bisphosphonates are similar (approximately 50%).
-
1 week ago | 
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.
-
1 week ago | 
rheumnow.com | Jack Cush
A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care. A post hoc study included pooled data from belimumab trials (Be-SLE; BLISS-52, BLISS-76, BLISS-SC, and EMBRACE) conducted between 2007 and 2018. Adults with active SLE were treated with either BEL (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy (ST).
-
1 week ago | 
rheumnow.com | Jack Cush
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. Overall, the goals of SLE management are to achieve remission or a low level disease activity, reduce morbidity and mortality, and minimize treatment-related adverse events.
-
1 week ago | 
rheumnow.com | Jack Cush
A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to reduced the risk of adverse pregnancy outcomes (APOs) in high-risk patients with APS.
-
2 weeks ago | 
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania. MTX works in pulmonary Sarcoid! NEJM reports Open label RCT of 138 un-Rx pulm. Sarcoid pts w/ either MTX or placebo. After 24 wks MTX was noninferior to PBO w/ mean change in FVC (-6.7 vs -6.1).
-
2 weeks ago | 
rheumnow.com | Jack Cush
A large randomized rheumatoid arthritis (RA) clinical trial compared subcutaneous tocilizumab (TCZ) vs oral methotrexate (MTX) vs. the combination of subcutaneous TCZ and MTX, and showed that TCZ was superior to MTX, either given as TCZ monotherapy or in combination with MTX. To evaluate the efficacy and safety of subcutaneous tocilizumab monotherapy, tocilizumab-methotrexate, and methotrexate alone for patients with RA.
-
2 weeks ago | 
rheumnow.com | Jack Cush
A prospective Danish rheumatoid arthritis (RA) registry study look at the risk of recurrence when a biological disease-modifying antirheumatic drugs (bDMARDs) was ued in patients with a a prior solid cancer (in remission) and found no increased cancer recurrence risk. The DANBIO ationwide registry examined RA patients with solid cancers in remission (breast, colorectal, melanoma, bladder, endometrial and lung) who were treated with either a bDMARD or a csDMARD.
-
2 weeks ago | 
rheumnow.com | Jack Cush
A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients than those with rheumatoid arthritis (RA), psoriasis (PsO) or psoriatic arthritis (PsA). Complex autoimmune disorders become more complex if the patient receives biologic therapy or if the patient becomes pregnant.
-
3 weeks ago | 
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com. Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too!• FDA approved the chikungunya virus vaccine (Ixchiq) in 11/23, but recently announced caution and pause use while it investigates Postmarketing Safety Reports of 17 SAE (cardiac & neurologic) & 2 deaths. 6 SAE in the USA, elderly w/ chronic med conditions.
